Oral Semaglutide Improves Blood Sugar, Weight, and Quality of Life in Real-World Type 2 Diabetes Patients | Research

The takeaway

In 61 real-world patients with type 2 diabetes, 6 months of oral semaglutide reduced HbA1c by 1.24%, improved body composition, lowered blood pressure, and significantly improved treatment satisfaction and quality of life.

HbA1c -1.24% with improved quality of life
Beyond metabolic improvements, patients on oral semaglutide reported significantly better treatment satisfaction and health-related quality of life — outcomes that matter for long-term medication adherence.

What the researchers found

After 6 months of oral semaglutide (14 mg/day) in 61 T2D patients: HbA1c decreased by 1.24% (SD 1.33, p significant), fasting plasma glucose decreased significantly, body composition and anthropometric parameters improved significantly, blood pressure decreased, cardiovascular risk factors improved, Diabetes Treatment Satisfaction Questionnaire (DTSQ) scores improved significantly, and SF-36 quality of life scores improved significantly. Average diabetes duration was 4.67 ± 3.93 years.

Why it matters

Treatment satisfaction and quality of life are critical but often overlooked in diabetes care. Many patients resist injectable medications, so an oral GLP-1 option that not only improves metabolic markers but also makes patients feel better about their treatment could improve long-term adherence. This is one of the few real-world studies capturing both clinical outcomes and patient-reported outcomes for oral semaglutide.

How the study worked

Prospective observational study with 6-month follow-up. Sixty-one subjects with type 2 diabetes were enrolled. Clinical parameters collected at baseline (T0) and 6 months (T1) included HbA1c, fasting plasma glucose, anthropometric measurements, blood pressure, cardiovascular risk factors, DTSQ (treatment satisfaction), and SF-36 (health-related quality of life).

What this study cannot tell us

Small sample size (61 patients) at a single site limits generalizability. No control group means improvements could be partly attributed to concurrent lifestyle changes, medication adjustments, or the Hawthorne effect. The 6-month follow-up is relatively short. The abstract mentions significant p-values but formatting errors prevent seeing specific values for several outcomes. Selection bias may favor motivated patients. The DTSQ and SF-36 improvements could reflect novelty of the medication rather than sustained satisfaction.

How to read the evidence

This is a small, single-center prospective observational study without a control group. While it captures valuable real-world and patient-reported data, the design cannot establish causation. The quality of life measures (DTSQ, SF-36) add a dimension often missing from diabetes studies.

When this study was published

Published in 2024, this study reflects the growing real-world experience with oral semaglutide since its approval, providing practical data to complement controlled trial evidence.

The bigger picture

Oral semaglutide represents a paradigm shift — the first oral GLP-1 receptor agonist, eliminating the injection barrier that prevents many patients from starting these effective drugs. This study adds to growing evidence that the oral formulation delivers comparable real-world benefits to injectable versions, while the quality of life data suggests patients actually prefer this treatment approach. As newer oral GLP-1 formulations are developed, this type of patient-centered outcome data becomes increasingly important.

Questions still open

Do the quality of life improvements persist beyond 6 months, or do they plateau or decline with time?
How does treatment satisfaction with oral semaglutide compare to injectable semaglutide in the same patient population?
Which specific SF-36 domains improved most — physical function, mental health, or social functioning?

Common questions

Does oral semaglutide work as well as the injection?

This real-world study shows oral semaglutide (14 mg daily) reduced HbA1c by 1.24% and improved weight, blood pressure, and cardiovascular risk factors over 6 months — results consistent with what's been seen with injectable semaglutide. While the study didn't directly compare oral to injectable, the metabolic improvements are in a similar range.

Do patients actually feel better on oral semaglutide?

Yes — this study measured both treatment satisfaction (DTSQ) and general quality of life (SF-36) and found significant improvements in both after 6 months. Patients were not only healthier by lab measures but also reported feeling better about their treatment and their overall health, which is important for sticking with long-term diabetes management.

Read the original research

Oral Semaglutide in Type 2 Diabetes: Clinical-Metabolic Outcomes and Quality of Life in Real-World Practice.

Journal of clinical medicine, 13(16)

View on PubMed ↗Publisher’s paper ↗

Citation

Pantanetti, Paola; Ronconi, Vanessa; Sguanci, Marco; Palomares, Sara Morales; Mancin, Stefano; Tartaglia, Francesco Carlo; Cangelosi, Giovanni; Petrelli, Fabio. (2024). Oral Semaglutide in Type 2 Diabetes: Clinical-Metabolic Outcomes and Quality of Life in Real-World Practice.. Journal of clinical medicine, 13(16). https://doi.org/10.3390/jcm13164752